06/22/2026
🔹 One of the biggest misconceptions in cell therapy development is that a high post-thaw viability is an indication of successful cryopreservation. When we have discussed with many groups about cryopreservation optimization, a common response we hear is, “Our post-thaw viability is +90%, we are OK.”.
🔹 Delayed Onset Cell Death (DOCD) occurs when accumulated stressors during processing tip the cells over the tolerable threshold into activation of irreversible apoptosis. We have seen it all - with T cells, NK cells, iPSCs, and many more.
🔹 These stressors can start accumulating throughout the process starting from days approaching harvest, to freezing, and post-thaw steps.
Is your process development team experiencing any of the following challenges?
❌ Poor functional recovery post-thaw
❌ Low post-thaw viability and/or recovery
❌ Process variability across donors, runs, and vials
❌ A novel cell type or seemingly non-cryopreservable cells
❌ Manufacturing scalability challenges
❌ Lack of internal biopreservation expertise
If you don’t know where to look to find answers and help with any of the above, it may be time to work with The Aby J. Mathew Center for Biopreservation Excellence (“The Center”).
The Center is equipped with experience, knowledge and equipment to offer you solutions in the form of scientific expertise, process development services, and training to help develop scalable, regulatory-aligned CGT workflows. ✔️
🎬 See how in our NEW video: https://youtu.be/tc4zfBnVTCw
Learn more about The Center’s services: https://go.biolifesolutions.com/The-Center
The Aby J. Mathew Center for Biopreservation Excellence (“The Cente...
